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variables, existing complications and treatment status) are used to estimate the
transition probabilities for different eventswithHbA1c acting as the key variable in
themodel. Patient behaviourwas also incorporated in the cost-effectivenessmodel
by updating HbA1c and other variables in time based on the patient’s behaviour.
Furthermore, the model is capable of performing probabilistic sensitivity analysis
allowing us to capture the effects of parameter uncertainty and report the likeli-
hood that interventions are cost-effective. RESULTS: A number of cost-effective
analyses were performed and the trade-offs between costs and QALYs are pre-
sented for different treatment/interventions. Screening strategies were also eval-
uated by comparing the cost savings and improvements in life expectancy.
CONCLUSIONS: The flexible individual patient level discrete event simulation
model developed enables cost-effectiveness evaluations of a number of treatments
and interventions for Type-1 diabetes. The model allows tracking the history of
each of the patients and this enables identification of different sub-groups for
targeted interventions.
DIABETES/ENDOCRINE DISORDERS – Patient-Reported Outcomes & Patient
Preference Studies
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COMPARING MEDICATION ADHERENCE, PERSISTENCE AND DISCONTINUATION
RATES TO PREGABALIN AND DULOXETINE AMONG TYPE 2 DIABETIC PATIENTS
Oladapo AO, Adeyemi A, Barner JC
The University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To compare medication adherence, persistence and discontinuation
rates tomedications used to treat painful diabetic peripheral neuropathy (PDPN) in
type 2 diabetic patients.METHODS: A retrospective cohort analysis of Texas Med-
icaid prescription claims data of type 2 diabetic patients between 18 and 64 years
whowere on either pregabalin or duloxetine. Datawere extracted from June 2003 to
October 2009. Eligible patients must have been on oral antidiabetic (OAD) medica-
tions at least 6months prior to the index date and have continuous eligibility for at
least 12 months post-index. Cohorts were constructed through propensity scoring
while controlling for baseline differences in demographics and pre-index medica-
tion use. The outcome variables were medication possession ratio (MPR), persis-
tence and discontinuation rates. Sensitivity analyses were conducted for both per-
sistence and discontinuation rates. RESULTS: The two study cohorts included 652
pregabalin and 652 duloxetine patientswith an overallmean age of 51.97.9.Mean
MPR for duloxetine (85.6%  18.2%) was significantly higher compared to pregaba-
lin (68.6% 25.0%); t 14.03; p□ 0.0001. The proportion of adherent patients
(MPR80%) on duloxetine (72.1%) was higher compared to pregabalin (40.2%); X2
134.74; p□0.001. Mean persistence for duloxetine (222.9 days  130.5) was signifi-
cantly longer compared to pregabalin (165.1 days 128.3)when a 60-day gap period
was used; t7.98; p□0.0001. Results of sensitivity analysis using 30, 90 and 120 days
gap periodswere robust. Also, the proportion of patients on duloxetine (65.5%)who
discontinued their medication was lower compared to pregabalin (79.8%) when a
90-day gap period was used (X2 38.94; p□0.0001). Results of sensitivity analysis
using 60 and 120 day gaps were also robust. CONCLUSIONS: Type 2 diabetes pa-
tients on duloxetine had significantly higher medication adherence and persis-
tence with lower discontinuation rates compared to patients on pregabalin.
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THE ECONOMIC IMPACT OF INCREASING THE LEVEL OF DRUG ADHERENCE IN
DIABETIC PATIENTS AT THE MEXICAN INSTITUTE OF SOCIAL SECURITY (IMSS)
Uc-Coyoc R, Arroyave-Loaiza MG, Lara-Gomez JE, Trejo-Amador U,
Rodriguez-Díaz Ponce MA
Instituto Mexicano del Seguro Social, D.F, Mexico
OBJECTIVES: The lack of adherence to diabetic drugsmay reduce the effectiveness
of the treatment increasing the hospitalization rates and costs. The purpose of this
study is to estimate the economic savings derived from comparing different dia-
betic drug adherence scenarios at the Mexican Institute of Social Security (IMSS).
METHODS: For patients with non-complicated diabetes mellitus, 19 pharmacolog-
ical treatment patterns and their distribution were identified by a panel of experts
from primary medical units and general and specialized hospitals. The total pop-
ulation of diabetic patients at IMSS in the year 2010was obtained from the diabetes
census; the percentage of patients under pharmacological treatment came from
the institutional health survey of 2010. Four drug adherence scenarios derived from
institutional studies were considered. All-cause hospitalization rates among dia-
betes drug adherent and non-adherent patients were derived from the interna-
tional literature due to the lack of national estimations. The annual total costs
included the pharmacological and all-cause hospitalization estimates for each
treatment pattern. The exchange rate was $12.34 pesos per dollar. RESULTS: The
metformin-glibenclamide combination was the most prescribed pharmacological
treatment at the Institute (26.6%) followed by metformin-insulin NPH (11.8%) and
metformin (11.2%). The diabetic drug adherence baseline scenario was 16%; this
was compared with three scenarios of 17.2%, 27% and 54.2% respectively. The
annual total costs were 6.05 times greater in non-adherent compared with adher-
ent patients in the baseline scenario. The economic savings increases as the level
of compliance scales up. This can be attributed to the cost reductions compared to
non-adherent patients mainly due to hospitalization. In the year 2010, savings
varied fromUSD$1.48million toUSD$47.01million.CONCLUSIONS:Health policies
that aim to increase adherence to diabetic drugs among patients are needed at the
institution in order to avoid unnecessary costs mainly among non-adherent pa-
tients.
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THE ASSOCIATION BETWEEN NON-ADHERENCE AND HBA1C AMONG TYPE 2
DIABETES PATIENTS USING BASAL INSULIN ANALOGUES
DiBonaventura MD1, Wintfeld N2, Goren A1
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OBJECTIVES: The aim of the current study was to determine the association be-
tweenmedicationnon-adherence andHbA1c levels among type 2 diabetes patients
currently using basal insulin analogues. METHODS: Data from the 2011 U.S. Na-
tional Health and Wellness Survey (NHWS) were used. The NHWS is a patient-
reported survey fielded to a demographically-representative sample of the adult US
population (N75,000). Analyses were restricted to those who reported a diagnosis
of type 2 diabetes, were currently using insulin glargine or insulin detemir, had
non-missing self-reported HbA1c values, and had non-missing medication adher-
ence data (assessed using the Morisky Medication Adherence Scale (MMAS)). The
association between medication non-adherence and HbA1c was examined using
multiple regressions controlling for sociodemographics, health behaviors, and
comorbidities. RESULTS: A total of 768 patients met the study inclusion criteria.
These patients weremostlymale (64.71%), had amean age of 61.39 (SD9.85), were
predominantly obese (72.92%), and reported a mean HbA1c level of 7.31%
(SD1.41%). A third of patients (33.20%) reported engaging in at least one non-
adherent behavior; the most common was being forgetful with their medication
(28.52%) followed by being careless with their medication (13.02%). Adjusting for
covariates, a higher non-adherence score was significantly associated with in-
creased HbA1c (b0.33, p.0001). When entering all non-adherent behaviors from
theMMAS separately into themodel being careless (b0.44, p.008) was the stron-
gest predictor of increased HbA1c levels. CONCLUSIONS: The results suggest that a
sizeable proportion of T2D patients using basal insulin analogues engage in some
form of non-adherent behavior, the most common being forgetfulness and care-
lessness with the administration of their medication. Even after adjusting for con-
founding variables, the presence of non-adherent behaviors (particularly careless-
ness) was associated with significantly higher levels of HbA1c. Improved
adherence of these patients may result in clinical benefits.
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INSTRUMENTS MEASURING TREATMENT ADHERENCE AND COMPLIANCE IN
DIABETES MELLITUS: A LITERATURE REVIEW
Rudell K1, Thrift-Perry M2, Savre I3, Perret C3, Caron M3
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OBJECTIVES: To provide an overview of subjective and objective measures used in
clinical trials to assess adherence or compliance to medical treatment in diabetes
mellitus, to identify trends in the measurement of adherence/compliance, stan-
dardization, and/or tool usage frequency.METHODS:The searchwas performed on
September 1, 2011 and was limited to articles written since 2000. The following
keywords and their descriptors inMedline viaOVIDwere used: patient compliance,
adherence, clinical trials, and diabetes mellitus. Once the abstracts had been re-
trieved, they were carefully reviewed and either selected or rejected, according a
ranking process. RESULTS: A total of 508 references were retrieved and 108 se-
lected. Forty-eight measures were identified: 36 to assess adherence, and 12 to
assess compliance. Among the adherence measures, 27 were subjective measures
such as patient-reported outcome (PRO) instruments and nine, objective. The
most-quoted subjectivemeasures usedwere theDiabetes Self-Management Profile
(DSMP) conventional or flexible regimen versions (four times); the Summary of
Diabetes Self-Care Activities (SDSCA) (four times); the five-itemMedication Adher-
ence Report Scale (MARS-5) (two times); theMoriskyMedication-Taking Adherence
Scale (MMAS) (two times); and the Brief Medication Questionnaire (BMQ) (two
times). Themost-quoted objectivesmeasures to assess adherencewere the refill of
repeat prescriptions (cited six times) and pill cap monitoring systems (five times).
As for the assessment of compliance, only two were subjective measures and ten
were objective. The PROmeasures retrieved were the Chronic Disease Compliance
Instrument and a Medication Compliance Scale. The most frequently used objec-
tivemeasure was the evaluation of return of study drugs. CONCLUSIONS:Diabetes
is a challenging disease to manage successfully and the associated costs of non-
adherence are high. This review shows a lack of standardization/consistency in the
measurement of adherence/compliance in diabetes. More research is needed on
what are the “best” tools to use tomeasure adherence-related behavior in diabetes.
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IMPACT OF ADHERENCE TO ORAL DIABETES MEDICATION ON SHORT-TERM
DISABILITY COSTS IN AN EMPLOYER POPULATION
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OBJECTIVES: The impact of adherence to hypoglycemic agents on the medical/
pharmacy costs of diabetes patients has been examined frequently in the litera-
ture, but the analogous impact on disability costs is not well-documented. This
study assesses the relationships between medication adherence and short-term
disability costs in a large manufacturing company. METHODS: A retrospective
analysis of pharmacy claims was conducted to identify individuals within a large
manufacturing company who were continuously eligible for a three-year time
frame (between 2001 and 2007) and who received a prescription for an oral hypo-
glycemic during that time; in those cases where an individual’s eligibility spanned
a longer time period, the most recent three-year span was chosen. Individuals on
insulin were excluded from the study population. The resulting sample included
both treatment-naïve and treatment-experienced patients, reflective of real-world
employer experience. Medical, pharmacy, and short-term disability costs were cal-
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culated for a one year follow-up. Adherence was measured using proportion of
days covered (PDC), where a PDC80 was considered adherent. Multi-variable lin-
ear regressionwas used to examine the relationships between cost and adherence,
controlling for patient demographics (age, gender, and job type) and Charlson co-
morbidity score. RESULTS:Among the 4978 individuals included in the study, the
average adherence to oral hypoglycemic agents was 72.7%, and 56.6% (N2820)
of the study population had a PDC80. The mean total medical/pharmacy costs
were similar for both the adherent and the non-adherent. Individuals who were
adherent to their diabetes medications, however, had significantly lower short-
term disability costs ($1161/year) than did the non-adherent ($1840/year).
CONCLUSIONS: In general, diabetes patients who adhered to their treatment reg-
imen had much lower short-term disability costs when compared to the non-
adherent. This result carries special implications for employers concernedwith the
total costs associated with diabetes in their employee populations.
PDB68
ADHERENCE TO ORAL ANTIDIABETIC MEDICATIONS IN THE PEDIATRIC
POPULATION WITH TYPE 2 DIABETES
Adeyemi A, Rascati KL, Strassels S, Lawson K
The University of Texas at Austin, Austin, TX, USA
OBJECTIVES: To assess adherence and persistence to OAD medications in the pe-
diatric population and to determine how adherence and persistence differ by age,
gender and race in the study population. METHODS: A retrospective cohort anal-
ysis of the Texas Medicaid prescription claims database. The study included pedi-
atric subjects (10-18 years) with type 2 diabeteswhohadOADmedications between
January 2006 and December 2009. Index date was defined as the date subjects had
their first OAD medication between January 1, 2006 and December 31, 2009. Pre-
scription claims were analyzed over a 6 month pre-index period through a 12-
month post-index period. Adherence was measured using the medication posses-
sion ratio (MPR). RESULTS: A total of 3,109 subjects met inclusion criteria. The
overall mean MPR SD was 44.69%  27.06. Adherence differed by gender
(p0.0001); race (p0.0001); and age category (p0.0001). Males had higher mean
MPR SD (47.47  27.42) compared to females (43.29  26.78). In addition, mean
MPR for whites (50.04 29.65) was significantly higher compared to blacks (44.24
26.16) and Hispanics (42.50  26.10). Subjects  12 years of age had significantly
highermeanMPR (48.82 27.27) compared to those in older age categories. Logistic
regression analysis revealed that age (continuous) was significantly related
(OR0.91; 95% CI0.87-0.95) to being adherent (MPR80%). Males were 25% (OR
1.25; 95%CI1.02-1.53; p0.034) more likely to be adherent (MPR80%) compared
to females andwhites were twicemore likely to be adherent (MPR80%) compared
to Hispanics (OR2.02; 95%CI1.54-2.66; p0.0012). The overall mean days to non-
persistence ( SD)was 108 days ( 86). Persistencewas significantly and negatively
associatedwith age (p 0.0001). Among the covariates,white racewas significantly
related to longer persistence. CONCLUSIONS: Adherence and persistence to OAD
medications in the study population is generally suboptimal.
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THE IMPACT OF NOCTURNAL HYPOGLYCEMIC EVENTS ON FUNCTIONING,
WELL-BEING AND DIABETES MANAGEMENT
Brod M1, Wolden M2, Pohlman B1, Christensen T3
1The Brod Group, Mill Valley, CA, USA, 2Novo Nordisk A/S, Søborg, Denmark, 3Novo Nordisk
A/S, Virum, Denmark
OBJECTIVES: Non-severe Nocturnal Hypoglycemic Events (NSNHEs) are hypogly-
cemic events that occur during sleep but don’t require medical assistance from
another individual. Impacts NSNHEs may have on are rarely studied and little is
known about how NSNHEs may affect patient functioning, well-being, and diabe-
tes management. METHODS: Nine focus groups were held in four countries
(France, Germany, United Kingdom, US) with diabetics who had experienced a
NSNHE within the previous month. Groups were audio-taped and analyzed the-
matically according to grounded theory principles of concept elicitation. RESULTS:
78 people with diabetes participated in the focus groups (53% female, 69% Type 2
diabetes, 65% insulin dependent). The average incident rate of NSNHEs was 4.0 per
month (range: 1-22.5). NSNHEs were thought to be more difficult to predict, under-
stand, or manage and created more worry than day time events. Thematic satura-
tion was reached after the 7th focus group. Major themes for both diabetes types,
defined as those that occurred in more than 5% of statements, were Next Day
Effects(17.3%), Symptoms (14.3%), Sleep Impacts (11.3%), Social Impacts (8.5%), Cor-
rective Action (8.5%), Practical Management (8.5%), Feelings about NSNHEs
(5.5%)and Work Impacts (5.5%). The negative effects of these areas of impacts
appear to be caused by the unique confluence of sleep disruption with the physi-
ologic effects of fluctuating blood sugars in the night and throughout the next day.
The following day 11% of respondents reported adjusting their insulin dose, 6%
monitored their blood sugars more frequently and 6% stated that they run their
sugars high before bedtime as a strategy for avoiding NSNHEs. CONCLUSIONS:
Both Type 1 and Type 2, insulin dependent and not, patients, experience NSNHEs
and the range of impact on these patients is wide with a majority of participants
experiencing strong impactswhich limit their daily functioning andwell-being and
affect their diabetes management strategies.
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OBJECTIVES: To assess health utilities and examine factors affecting health utili-
ties among patientswith type 2 diabetesmellitus (T2DM) in China.METHODS:Data
were obtained from a cross-sectional survey of T2DM patients in outpatient set-
tings from October to December, 2011 in Beijing and Tianjin. Eligible patients were
18 years, had a diagnosis of T2DM 1 year and received 1 year anti-diabetic
treatment. Health utility was measured using The Chinese version of EQ-5D. The
EQ-5D index score and visual analog scale (VAS) score were calculated for all T2DM
patients and subgroups defined by fasting blood glucose control (FBG8 mmol/L)
and complications. Multivariate linear regressions were conducted to assess fac-
tors associated with health utilities such as patient demographics, glucose control,
complications, and lifestyle variables. RESULTS: A total of 588 patients were in-
cluded with 54.9% female, mean age of 63.3 years and mean disease duration of 11.3
years. About 64.5% patients had FBG control. Most patients (94.9%) had1 complica-
tion: macrovascular complications (50.9%), retinopathy (59.1%), nephropathy (28.6%),
neuropathy (52.3%). Mean EQ-5D and VAS scores for all patients were 0.78 and 64,
respectively. Mean EQ-5D score was higher among patients with FBG control versus
those without (0.80 vs. 0.75, p0.003). Patients with macrovascular complications,
retinopathy, nephropathy and neuropathy had significantly lower EQ-5D score com-
pared to those without the corresponding complications (0.73 vs. 0.82, 0.75 vs. 0.83,
0.74 vs. 0.80, and 0.73 vs. 0.84, respectively; all P0.001). Similar results were observed
for EQ-VAS in these comparisons. Macrovascular complications and somemicrovas-
cular complications (e.g., nephropathy and neuropathy) were negatively associated
with health utilities while education and exercise were positively associated with
health utilities. CONCLUSIONS: Compared to the general Chinese population (EQ-
VAS of 80), patients with T2DM have impaired quality of life. Factors affecting
health utilities may include complications, education and exercise.
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HEALTH RELATED QUALITY OF LIFE IN KIDNEY TRANSPLANT PATIENTS WITH
DIABETES
Neri L1, Dukes J2, Lentine K2, Schnitztler M2
1University of Milan, Milan, Italy, 2Saint Louis University, St. Louis, MO, USA
OBJECTIVES:We sought to assess the disutility associated with diabetes after kid-
ney transplant. METHODS: We enrolled 233 kidney transplant recipients aged
18-74 years (response rate 79%) from a Midwestern hospital outpatient department.
Recipients with multiple or multi-organ transplants, those with laboratory evidence
that suggests acute cellular damage (Creatinine-Kinase 200 U/L), or a diagnosis of
acute renal failure or acute rejection were excluded from the analysis (n33). Partici-
pants HRQOLwere evaluated using the Euro-QoL-5 Dimension (EQ-5D), Health Utility
IndexMark III (HUI-III), and the Short Form-6D (SF-6D) whichwas calculated from the
generic section (SF-12) of the Kidney Disease Quality of Life 36 (KDQOL-36). We esti-
mated health utilities associated with diabetes using General Linear Modeling after
adjusting for demographic, socio-economic, and clinical characteristics. RESULTS:
The adjusted Health disutilities associated to diabetes were clinically and statisti-
cally significant: EQ-5D (	0.05; p0.01), HUI-III (	0.09; p0.01), and SF-6D
(	0.04, p0.01). There was no difference between diabetic patients with good gly-
cemic control (mean serum glucose 126mg/dL in the 3 months prior to enrollment)
and patients with poor glycemic control. CONCLUSIONS: Among kidney transplant
patients between the ages of 18 to 74, non-diabetics have significantly higher
HRQOL scores on the EQ-5D, HUI-III, and SF-6D compared to diabetic patients.
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THE IMPACT ON UTILITIES OF WEIGHT LOSS AND WEIGHT GAIN AMONG
CANADIAN PATIENTS WITH TYPE 2 DIABETES
Lane S1, Levy AR1, Sambrook J1, Mukherjee J2, Leahy M2, Tildesley H3
1Oxford Outcomes Ltd., Vancouver, BC, Canada, 2Bristol-Myers Squibb Company, Wallingford,
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OBJECTIVES: There is evidence in the literature linking weight gain on anti-diabetic
medication to impact on psychosocial well-being and non-compliance in type 2 dia-
betes (T2D). Due to the lack of data on the impact of weight loss and the imminent
introduction of a new class of oral agents (SGLT2 inhibitors) with demonstrated
weight-loss properties, this studywas designed to compare the impact of weight gain
and weight loss on utilities among Canadian T2D patients.METHODS: Health states
included a T2D base-case health state and six additional weight change health states
(base-case 3%, 5%, and 7% weight change relative to current weight). Utilities
wereelicitedusing timetrade-off techniques. Enrollment requirements included:hav-
ingT2D for at least twoyears, adequate control onantidiabeticmedication, not receiv-
ing insulin, and not enrolled in a T2D clinical trial. RESULTS: Among 96 respondents
(mean age 55 years; 51%male; mean bodymass index (BMI) 32 kg/m2) 84% expressed
a desire to lose weight. The mean utility (standard error (SE)) for the base-case T2D
health state was 0.911 (0.013). The utility decreased to 0.907 (0.013), 0.865 (0.014) and
0.806 (0.017) for the 3%, 5% and 7% weight gain health states, respectively, and in-
creased to 0.923 (0.012), 0.940 (0.011) and0.949 (0.010) for the 3%, 5%and7%weight loss
health states, respectively. Linear mixed models indicated that a change in weight
leading to a one unit increase and decrease in BMI had significant effects (SE) on
utilities of -0.0472 (0.005) and 0.0171 (0.003), respectively. CONCLUSIONS: We ob-
served a dose-response relationship betweenweight change and patient-elicited util-
ities in T2D health states with weight gain having a stronger effect than weight loss.
Theweight-loss properties of SGLT2 inhibitorsmay improveutilitieswhile preventing
the disutility associated with weight gain, which may positively impact treatment
compliance and health outcomes.
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